Amgen Inc. Restructuring Charges
Amgen Inc. (AMGN) reported Restructuring Charges of $267.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-02-14
- Amgen Inc. restructuring charges for the quarter ending 2023-12-31 was $15.00M.
- Amgen Inc. restructuring charges for the quarter ending 2023-09-30 was $31.00M.
- Amgen Inc. restructuring charges for the quarter ending 2023-06-30 was $42.00M.
- Amgen Inc. restructuring charges for the quarter ending 2023-03-31 was $179.00M.
- Amgen Inc. restructuring charges for fiscal 2023 was $267.00M.
- Amgen Inc. restructuring charges for fiscal 2017 was $79.00M, a 315.79% increase from fiscal 2016.
- Amgen Inc. restructuring charges for fiscal 2016 was $19.00M, a 85.61% decline from fiscal 2015.
- Amgen Inc. restructuring charges for fiscal 2015 was $132.00M, a 65.71% decline from fiscal 2014.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2023-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $46.00M derived: sum of 2 quarters · filed 2024-02-14 | $88.00M derived: sum of 3 quarters · filed 2024-02-14 | $267.00M 10-K · filed 2024-02-14 |
| 2023-09-30 | $31.00M 10-Q · filed 2023-10-31 | $73.00M derived: sum of 2 quarters · filed 2023-10-31 | $252.00M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $42.00M 10-Q · filed 2023-08-04 | $221.00M 10-Q · filed 2023-08-04 | ||
| 2023-03-31 | $179.00M derived: 10-K 12 month − 3 quarters · filed 2024-02-14 | |||
| 2017-12-31 | $79.00M 10-K · filed 2018-02-13 | |||
| 2016-12-31 | $19.00M 10-K · filed 2018-02-13 | |||
| 2015-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $37.00M derived: sum of 2 quarters · filed 2018-02-13 | $75.00M derived: sum of 3 quarters · filed 2018-02-13 | $132.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $58.00M derived: sum of 2 quarters · filed 2015-11-02 | $115.00M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $38.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $95.00M 10-Q · filed 2015-08-05 | ||
| 2015-03-31 | $57.00M 10-Q · filed 2015-04-27 | |||
| 2014-12-31 | $385.00M 10-K · filed 2018-02-13 | |||
| 2014-09-30 | $312.00M 10-Q · filed 2014-10-29 | |||
| 2009-12-31 | $34.00M 10-K · filed 2011-02-25 | |||
| 2008-12-31 | $92.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |